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BACKGROUND: Early stage bladder cancer is a heterogeneous disease with a variable risk of progression and mortal-
ity. Uncertainty surrounding the optimal care for these patients may result in a mismatch between disease risk and
treatment intensity. METHODS: Using Surveillance, Epidemiology, End Results-Medicare data, we identified patients
diagnosed with early stage bladder cancer (n ¼ 24,980) between 1993 and 2002. We measured patients’ treatment
intensity by totaling all Medicare payments made for bladder cancer in the 2 years after diagnosis. Using multiple
logistic regression, we assessed relationships between clinical characteristics and treatment intensity. Finally, we
determined the extent to which a patient’s disease risk matched with their treatment intensity. RESULTS: The average
per capita expenditures increased from $6,936 to $7,642 over the study period (10.2% increase; P < .01). This increase
was driven by greater use of intravesical therapy (2.6 vs 3.7 instillations per capita, P < .01) and physician office visits
(3.0 vs 4.8 visits per capita, P < .01). Generally, treatment intensity was appropriately aligned with many clinical char-
acteristics, including age, comorbidity, tumor stage, and grade. However, treatment intensity matched disease risk for
only 55% and 49% of the lowest and highest risk patients, respectively. CONCLUSIONS: The initial treatment intensity
of early stage bladder cancer is increasing, primarily through greater use of intravesical therapy and office visits.
Treatment intensity matches disease risk for many, but up to 1 in 5 patients may receive too much or too little care,
suggesting opportunities for improvement. Cancer 2010;116:2604–11. VC 2010 American Cancer Society.
KEYWORDS: urinary bladder neoplasms, health expenditures, cost savings, guideline adherence.
Early stage (ie, superficial, or nonmuscle invasive) bladder cancer is a heterogeneous disease with variable risk of recur-
rence, progression, and death. Low-risk tumors (eg, Ta and low grade) commonly recur but are rarely lethal in the absence
of progression.1 In contrast, more aggressive cancers (eg, T1, high grade) frequently progress to muscle-invasive disease,1
from which mortality is high. Clinical data suggest that traditional methods of surveillance and treatment do not improve
survival.2 In fact, patients who progress under a watchful eye may fare worse than those who initially present with invasive
cancers.3
Although clinical guidelines provide a framework for managing patients with varying levels of disease risk,4 the evidence
base underlying treatment recommendations is imperfect. In light of the uncertainty surrounding how best to care for those
with early stage bladder cancer, urologists vary widely in how aggressively they manage their patients.5 Perhaps more impor-
tantly, intensive management of these patients, implicit in current guidelines, has not necessarily improved imperative out-
comes, such as survival. For example, while intensive use of intravesical therapy can prolong the interval between disease
recurrences, the extent to which it improves survival or prevents progression is uncertain.6,7 In contrast, other recommended
practices, such as frequent cystoscopy,8 have theoretical advantages but lack empirical support demonstrating a benefit.
Recognizing that the optimal approach for caring for patients with early stage bladder cancer is unknown, we
explored secular trends in its management and identified relationships between clinical characteristics and initial treatment
intensity. Finally, we evaluated the extent to which treatment intensity paralleled the risk posed by bladder cancer.
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Using Surveillance Epidemiology and End Results
(SEER)-Medicare data, we identified patients diagnosed
with bladder cancer for the years 1993 through 2002.
Using Medicare claims, patients were followed through
December 31, 2005. As detailed elsewhere,9 SEER-
Medicare data provide a rich source of information on
Medicare patients included in SEER, a nationally repre-
sentative collection of population-based cancer registries.
During the study period, the SEER registries coverage
increased from about 14% of the US population (1993 to
1999) to approximately 26% of the US population (2000
to 2002).10 The linked data comprise 100% of the Medi-
care claims from the inpatient, outpatient, and national
claims history files. This study was limited to patients
with early stage bladder cancer (modified American Joint
Commission on Cancer, 3rd edition, stage 0 and 1)11 and
to those fee-for-service beneficiaries with continuous
enrollment in Medicare Parts A and B commencing with
the year prior to diagnosis. Patients who underwent cys-
tectomy within 6 months of diagnosis were excluded from
this analysis as they may have harbored more aggressive
disease that was downstaged (eg, clinical T2 to pathologic
T1) on pathologic analysis of the bladder.
Using this approach, our final cohort comprised
24,980 patients.
Outcomes
Our primary outcome was patient-level treatment inten-
sity, as measured by all Medicare payments for bladder
cancer that incurred within the first 2 years after diagnosis.
Using inpatient and outpatient claims, we included those
expenditures associated with a primary diagnosis code for
bladder cancer (International Classification of Diseases,
9th Revision, [ICD-9] diagnosis codes: 188.x-bladder
cancer, 233.7-carcinoma in situ of the bladder, and
V10.51-personal history of bladder cancer). Medicare
payments were standardized to 2005 dollars using the
Medicare Economic Index12 and were price-adjusted to
account for regional variation in Medicare reimburse-
ment. Through these adjustments, expenditure data
reflect the intensity at which services were provided to
patients and could be compared across years and regions.
To illustrate relationships between clinical characteristics
and the treatment intensity received, we sorted patients
into 3 equally sized groups of low, medium, and high ini-
tial treatment intensity.
To understand the care underlying differences in in-
tensity, we characterized health care services commonly
used in early stage bladder cancer patients. Using the
ICD-9 procedure and Healthcare Common Procedure
Coding System codes within the Medicare files, we identi-
fied surveillance-related services (endoscopic examination
of the bladder, upper urinary tract evaluation, urinary
tests, radiographic imaging studies, and office visits to the
physician primarily responsible for each patient’s bladder
cancer care) and treatment-related services (intravesical
therapy and restaging transurethral resection). Finally,
payments for bladder cancer services were then tallied by
type (provider, hospital, or institutional outpatient) to
understand where changes in spending were occurring
over time.
Characterizing Bladder Cancer Risk
Because of the chronic nature of early stage bladder cancer
in many patients, competing causes for mortality are par-
ticularly important when considering the risk posed by
the cancer.13 Although ill-defined,14,15 most would agree
that there are combinations of age, comorbidity, and dis-
ease severity that confer varying levels of risk of bladder
cancer death among those with early stage disease. For
example, an 85-year-old with multiple comorbid illnesses
diagnosed with a low-grade Ta cancer has a lower risk of
cancer-related death than a healthy 65-year-old diagnosed
with a high-grade T1 cancer. Because our intent was to
assess how treatment intensity parallels bladder cancer
risk, we identified groups of patients with very low risk
and very high risk of bladder cancer-related death. Our
group with the lowest risk of bladder cancer death
included patients at least 85 years of age with two or more
comorbid illnesses and low-grade Ta bladder cancer. Our
group with the highest risk included patients less than 75
years of age with no more than 1 comorbid illness, and
carcinoma in situ or T1 bladder cancer. Our intent was
not to identify all high risk and low risk patients; rather,
we wanted to explore treatment intensity at the margins of
bladder cancer risk.
Statistical Analysis
We measured temporal changes in the initial treatment
intensity and use of bladder cancer services on a yearly ba-
sis. Because of the addition of four new SEER registries in
2000, we stratified the data by time period (SEER 13,
years 1993 to 1999 and SEER 17, years 2000 to 2002).
Statistical inference was made using linear regression or
chi-squared tests for continuous and categorical data,
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Table 1. Secular Changes in Clinical Characteristics of the Bladder Cancer Population
SEER 13 SEER 17
Year of Diagnosis P Year of Diagnosis P
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
No. of patients 1745 1807 1769 1853 1759 1907 1943 3954 4103 4140
Age, y (mean) <.01 .27
77.0 76.9 77.1 77.6 77.4 77.7 77.7 77.9 77.9 78.1
Age, y (%) <.01 .69
65-69 16.8 16.8 18.0 15.4 14.0 13.5 13.8 13.6 13.2 12.6
70-74 26.2 26.8 25.3 23.5 27.2 23.9 25.4 23.2 24.0 23.3
75-79 24.6 25.3 24.1 26.2 25.9 27.8 25.9 26.9 25.9 26.1
80-84 19.3 17.9 18.4 17.9 18.3 19.7 18.3 20.5 20.3 21.5
851 13.1 13.2 14.2 17.0 14.6 15.1 16.6 15.8 16.6 16.5
Women (%) .81 .08
25.9 26.1 27.7 26.3 25.4 26.0 25.8 26.5 24.7 24.6
Race (%) .10 .04
White 94.7 94.7 94.6 94.4 93.4 94.1 92.6 94.9 93.8 93.3
Black 3.0 3.1 2.6 2.8 3.8 2.8 4.1 2.7 3.0 3.2
Other 2.3 2.2 2.8 2.8 2.8 3.1 3.3 2.4 3.2 3.5
Socioeconomic status (%) .55 .64
Low 30.7 32.2 30.5 31.3 30.9 31.0 29.4 35.2 35.1 34.8
Medium 34.8 33.4 36.7 33.9 33.1 33.8 34.6 31.8 33.1 33.0
High 34.5 34.4 32.8 34.8 36.0 35.2 36.0 33.0 31.8 32.2
Comorbidity (%) .14 .91
0 70.0 69.3 69.2 69.0 67.4 66.7 65.3 62.3 62.0 62.2
1 19.3 18.8 19.7 19.6 21.4 20.8 22.7 23.0 23.5 22.6
2 6.8 7.4 6.8 7.9 6.7 7.6 7.3 8.9 8.7 9.0
31 3.9 4.5 4.3 3.5 4.5 4.9 4.7 5.8 5.8 6.2
Tumor classification <.01 .10
Ta 54.1 54.4 56.3 58.2 59.0 57.8 53.1 53.8 52.0 54.6
Tis 7.6 6.1 5.9 8.5 8.6 8.1 7.9 6.6 7.6 6.6
Ta, Tis, NOS 11.6 12.7 12.5 9.1 8.0 10.1 13.5 14.6 13.8 13.4
T1 26.7 26.8 25.3 24.2 24.4 24.0 25.5 25.0 26.6 25.4
Tumor grade <.01 .23
1 20.3 20.0 18.9 21.0 20.6 18.0 17.9 20.1 19.6 19.1
2 46.7 47.9 47.3 46.4 48.1 46.5 45.6 41.9 41.2 40.6
3 to 4 25.6 24.5 26.3 25.2 24.1 28.5 30.5 30.8 30.6 31.8
Unknown 7.4 7.6 7.5 7.4 7.2 7.0 6.0 7.2 8.6 8.5
SEER region .10 .26
Seattle (Puget Sound) 11.8 9.5 11.4 11.7 10.2 11.5 11.6 5.3 5.7 6.4
Atlanta 5.3 4.7 4.3 5.0 4.8 4.1 5.3 2.7 2.7 2.1
Connecticut 15.5 16.5 15.3 16.4 14.7 15.2 16.2 7.7 7.1 7.5
Detroit 17.8 17.8 18.8 17.0 19.4 17.3 17.8 8.7 8.6 8.3
Hawaii 1.2 1.1 1.6 1.5 1.2 2.0 1.2 0.9 0.9 1.2
Iowa 14.7 14.8 16.0 14.7 17.7 16.9 14.9 7.7 7.9 6.8
New Mexico 3.6 4.0 3.4 3.5 2.9 4.0 3.7 1.6 1.8 1.9
Rural Georgia 0.1 0.4 0.4 0.1 0.4 0.2 0.2 0.2 0.2 0.1
Utah 3.6 4.5 4.2 4.3 3.8 3.8 5.6 2.4 2.8 2.2
Californiaa 26.4 26.7 24.6 25.8 24.9 25.0 23.5 30.5 29.1 29.6
Kentucky 7.4 7.5 8.1
Louisiana 5.6 5.3 6.2
New Jersey 19.3 20.4 19.6
SEER indicates Surveillance, Epidemiology, End Results.
a California includes the San Francisco, Los Angeles, and San Jose/Monterey registries in the SEER 13 data. In the SEER 17 data, California also includes
greater California.
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respectively. We further assessed temporal trends in treat-
ment intensity by evaluating changes in the types of Medi-
care payments (hospital, institutional outpatient, and
physician) over time, using linear regression, again strati-
fied by time period.
We then measured the relationships between treat-
ment intensity (low, medium, high) and clinical character-
istics, including age (5-year age groups), sex, race (white,
black, or other), socioeconomic status, level of comorbid-
ity, tumor grade (low, medium, high, or unknown), tumor
stage (Ta, Tis, T1, early stage not otherwise specified),11
and SEER region. The early stage, not otherwise specified
group (Ta, T1, NOS) was recorded by the SEER registrars
as a separate category from the Ta or T1 tumors. We ascer-
tained a patient’s socioeconomic status by using a compos-
ite measure as described by Diez-Roux.16 Patient
comorbidities were identified using all healthcare encoun-
ters in the 12-month period preceding the bladder cancer
diagnosis, using the well-established methods described by
Klabunde and colleagues.17 We fitted a multiple logistic
regression model to measure the independent relationship
between patient characteristics and treatment intensity
stratified by the year of SEER registry expansion. Finally,
we characterized treatment intensity patterns among
patients in our highest and lowest risk groups to better
understand how intensity varies with risk.
All testing was conducted using SAS version 9.1.2
(SAS Institute, Cary, NC), using 2-sided tests. The proba-
bility of Type 1 error was set at 0.05. The study protocol
was approved by the University of Michigan’s Institu-
tional Review Board.
RESULTS
Changes in treatment intensity occurred in the back-
ground of little variation in overall patient and tumor
characteristics (Table 1). Over the first 7 years of the study
(SEER 13), the average patient age increased from 76.9 to
77.7 years (P < .01) and the percentage of white patients
decreased from 94.5% to 92.2% (P < .01). Although tu-
mor stage remained fairly stable, the proportion of high-
grade tumors increased from 26.2% to 31.6% (P < .01).
Over the last 3 years of the study (SEER 17), patient age,
tumor grade, and tumor stage all remained stable.
Despite these small changes in case mix, overall utili-
zation increased significantly over the first 7 years of the
study. As illustrated in Figure 1, treatment expenditures
for the first 2 years of bladder cancer care increased from
$6,936 to $7,602 per capita (P < .01 for trend). This
increase was primarily because of the greater use of institu-
tional outpatient services ($2,915 to $4,053 per capita; P
Figure 1. Per capita Medicare payments (standardized to
2005 dollars and price adjusted by region) for early stage
bladder cancer therapy in the Surveillance, Epidemiology,
End Results (SEER) 13 and 17 cohorts is depicted. Overall per
capita utilization increased in the SEER 17 cohort, driven by
increased institutional outpatient expenditures. The use of
physician services also increased but did not achieve statisti-
cal significance.
Figure 2. As shown, endoscopic surveillance was the most
common service but remained relatively stable throughout
the study. The use of intravesical therapy and physician visits
increased. Higher proportions of patients received induction
intravesical therapy, but the use of restaging transurethral
resection of bladder tumor and urinary cytology tests
showed no significant linear trends over time.
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Table 2. Relation Between Patient Factors and Treatment Intensity
SEER 13 SEER 17
Treatment
Intensity
Adjusteda OR (95% CI) Treatment
Intensity
Adjusteda OR (95% CI)
Low Med High High vs Low Low Med High High vs Low
No. of patients 4257 4256 4270 4062 4061 4074
Age, y
65-69 32.1 33.4 34.5 1.0 32.9 32.4 34.7 1.0
70-74 31.0 34.1 34.9 0.99 (0.85, 1.15) 30.9 33.7 35.4 1.09 (0.93, 1.27)
75-79 31.3 33.6 35.1 0.97 (0.83, 1.20) 31.3 33.8 34.9 1.08 (0.93, 1.26)
80-84 33.9 33.8 32.3 0.81 (0.69, 0.94) 34.3 32.5 33.2 0.88 (0.75, 1.04)
851 41.2 30.7 28.1 0.54 (0.46, 0.64) 39.0 33.5 27.5 0.59 (0.50, 0.71)
Sex
Men 33.4 32.9 33.7 1.0 33.4 33.2 33.4 1.0
Women 33.1 34.4 32.5 1.02 (0.92, 1.14) 33.1 33.6 33.3 1.08 (0.97, 1.20)
Race
White 33.3 33.5 33.2 1.0 33.1 33.4 33.5 1.0
Black 30.0 27.5 42.5 1.21 (0.92, 1.59) 36.9 27.3 35.8 0.90 (0.69, 1.18)
Other 38.6 33.2 28.2 0.74 (0.54, 1.03) 35.3 35.3 29.4 0.84 (0.63, 1.14)
Socioeconomic status
Low 32.4 31.6 36.0 1.0 33.0 33.5 33.5 1.0
Medium 33.1 33.9 33.0 0.99 (0.88, 1.12) 34.5 33.1 32.4 1.00 (0.89, 1.12)
High 34.3 34.3 31.4 0.97 (0.85, 1.09) 32.5 33.3 34.2 1.20 (1.06, 1.36)
Modified Charlson index
0 32.7 33.3 34.0 1.0 31.9 33.5 34.6 1.0
1 33.2 33.7 33.1 0.96 (0.86, 1.08) 32.9 33.8 33.3 0.94 (0.84, 1.06)
2 35.4 32.8 31.8 0.89 (0.74, 1.06) 37.4 33.8 28.8 0.72 (0.61, 0.86)
31 40.6 32.3 27.1 0.59 (0.47, 0.74) 43.2 29.3 27.5 0.58 (0.47, 0.70)
Tumor classification
Ta 37.9 34.3 27.8 1.0 36.8 34.0 28.2 1.0
Tis 28.4 32.7 38.9 1.49 (1.22, 1.80) 28.0 31.0 41.0 1.86 (1.65, 2.10)
Ta, Tis, NOS 33.3 35.2 31.5 1.21 (1.04, 1.41) 38.0 33.2 28.8 1.00 (0.86, 1.15)
T1 23.5 30.7 45.8 1.92 (1.70, 2.17) 24.5 30.8 44.7 1.61 (1.32, 1.95)
Tumor grade
Low 43.6 36.3 20.1 1.0 43.5 34.3 22.2 1.0
Medium 34.9 33.9 31.2 2.03 (1.78, 2.31) 35.4 35.3 29.3 1.57 (1.37, 1.78)
High 23.9 31.0 45.1 4.06 (3.47, 4.74) 24.7 30.5 44.8 3.08 (2.66, 3.57)
Unknown 29.4 29.7 40.9 3.20 (2.57, 3.99) 30.9 31.6 37.5 2.20 (1.79, 2.70)
SEER region
Seattle (Puget Sound) 41.6 34.2 24.2 1.0 35.1 34.1 30.8 1.0
Atlanta 28.4 34.1 37.5 2.65 (2.04, 3.44) 34.3 32.3 33.4 1.22 (0.87, 1.73)
Californiab 36.0 34.7 29.3 1.71 (1.43, 2.03) 35.8 34.0 30.2 1.13 (0.92, 1.40)
Connecticut 32.2 35.0 32.8 2.19 (1.82, 2.64) 29.2 36.8 34.0 1.51 (1.17, 1.95)
Detroit 29.8 30.4 39.8 3.13 (2.61, 3.75) 24.8 28.5 46.7 2.73 (2.12, 3.50)
Hawaii 38.9 27.2 33.9 2.01 (1.29, 3.13) 25.2 31.9 42.9 2.41 (1.42, 4.10)
Iowa 28.4 31.8 39.8 3.21 (2.66, 3.87) 27.1 35.9 37.0 2.16 (1.67, 2.81)
New Mexico 33.6 32.4 34.0 2.29 (1.72, 3.03) 33.0 33.5 33.5 1.39 (0.93, 2.08)
Rural Georgia 19.4 41.9 38.7 4.40 (1.46, 13.3) 33.3 28.6 38.1 1.87 (0.65, 5.42)
Utah 37.1 35.5 27.4 1.57 (1.20, 2.05) 33.8 35.1 31.1 1.26 (0.89, 1.79)
Kentucky 30.9 33.6 35.5 1.71 (1.32, 2.23)
Louisiana 30.6 35.2 34.2 1.78 (1.34, 2.36)
New Jersey 38.6 31.2 30.2 1.05 (0.85, 1.31)
OR indicated odds ratio; CI, confidence interval; NOS,not otherwise specified; SEER, Surveillance, Epidemiology, End Results.
a Adjusted for age, race, gender, socioeconomic status, tumor classification, tumor grade, and SEER region.
bCalifornia includes the San Francisco, Los Angeles, and San Jose/Monterey registries in the SEER 13 data. In the SEER 17 data, California also includes
greater California.
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< .01 for trend). For patients diagnosed in the last 3 years
of the study, overall expenditures for bladder cancer care
appear to have stabilized; however, per capita expendi-
tures for care in the institutional outpatient setting contin-
ued to increase ($3,552 in 2000 to $3,824 in 2002; P ¼
.04). Among physician services, endoscopic surveillance
was the most common (Figure 2), although its use
remained relatively steady across both the SEER 13 and
the SEER 17 cohorts. In contrast, intravesical therapy
(2.6 vs 3.3 instillations per patient in the earliest vs latest
group, respectively; P< .01 for trend) and physician visits
(3.0 vs 3.7 visits per patient in the earliest vs the latest
group, respectively, P < .01 for trend) increased substan-
tially in the SEER 13 cohort. Within the SEER 17 cohort,
only physician visits increased significantly (4.1 vs 4.8 vis-
its per patient in the earliest vs latest group, respectively; P
< .01 for trend).
Patient demographic, health, and tumor characteris-
tics had strong associations with early stage bladder cancer
treatment intensity in both the SEER 13 and SEER 17
cohorts (Table 2). Tumor grade and stage were strongly
associated with greater intensity treatment. Compared
with those with Ta tumors, patients with T1 cancers were
nearly twice as likely to receive the most intensive care
(odds ratio [OR], 1.92; 95% confidence interval [CI],
1.70 to 2.97, SEER 13; and OR, 1.61; 95% CI, 1.32 to
1.95, SEER 17]. Similarly, patients with high-grade
tumors were more than 3 times more likely to receive high
intensity care (OR, 4.06; 95%CI, 3.47 to 4.74, SEER 13;
OR, 3.08; 95% CI, 2.66 to 3.57, SEER 17). Conversely,
older age and increasing comorbidity were associated with
lower intensity care.
As illustrated in Figure 3, treatment intensity
matched cancer severity for 55% and 49% of low-risk and
high-risk patients, respectively. In other words, for many
patients at the extremes of risk related to bladder cancer,
treatment intensity did not parallel disease risk. Nine per-
cent of patients with the lowest risk disease received high-
intensity care, and 21% of those with the most aggressive
disease received low-intensity care.
DISCUSSION
Although the proportion of patients diagnosed with Ta,
T1, and Tis bladder cancer remained consistent over the
10-year study interval, locations of care for bladder can-
cer-related services shifted significantly, and overall per
capita expenditures increased by over 10%. Growing
Medicare payments for the initial management of early
stage bladder cancer were largely because of increasing use
of intravesical therapy and office visits and a shift in care
to the institutional outpatient setting. On average, treat-
ment intensity appeared to be appropriately aligned with
many clinical characteristics, including age, comorbidity,
and cancer stage and grade. However, even as treatment
intensity paralleled disease risk for many, up to 1 in 5
patients with the highest and lowest risk disease were
managed discordantly with their cancer severity, suggest-
ing opportunities for improvement.
The secular trend for increasing physician treatment
intensity may be explained, to some degree, by the
uncertainty surrounding contemporary practice guide-
lines.4,18,19 Although these guidelines offer recommenda-
tions in how to approach patients with early stage bladder
cancer, they fall short of defining the optimal care, neces-
sarily leaving decision making in the hands of the physi-
cian. Because of the limited evidence base, consensus
guideline recommendations lack stringency and generally
favor more intensive care, despite the economic implica-
tions and the possibility that such care has little added
value for the patient.20 Bladder cancer already ranks
among the most expensive cancers to treat from diagnosis
to death,21 in part because of its chronic nature and the
growing population with early stage disease. As the US
population ages, the disease’s prevalence will invariably
increase and related health-care costs are sure to rise. For
this reason, eliminating potentially unnecessary care
would likely yield a cost-savings to the already strapped
Medicare program and mitigate the unintended conse-
quences associated with overuse.
Figure 3. Treatment intensity in low-risk and high-risk bladder
cancers are depicted. The lowest risk of progression and re-
currence category includes patients over 85 years of age
with two or more comorbidities and Ta low-grade disease are
depicted. The highest risk category includes patients 65 to 74
years of age with no more than 1 comorbidity and T1 disease
or carcinoma in situ.
Early Stage Bladder Cancer Care Patterns/Strope et al
Cancer June 1, 2010 2609
An additional limitation of the early stage bladder
cancer guidelines is that they restrict their guidance solely
based on disease severity (ie, cancer stage and grade),
excluding several important patient factors. Bladder can-
cer is predominantly a disease of the elderly, with nearly
three-quarters of cases occurring in patients aged 65 years
and older.10 Unlike muscle-invasive cancer, which has
high mortality rates,22,23 early stage bladder cancer is gen-
erally a chronic disease, with a protracted and often indo-
lent course.6 This natural history, coupled with high rates
of competing-cause mortality24 in the elderly, suggests
that a treatment approach tailored to disease and compet-
ing risks would improve the quality of care delivered to
this population. Just as failure to aggressively treat a high-
grade T1 cancer would represent poor quality, so too
would the intensive treatment of a rarely lethal low-grade
Ta tumor in an elderly patient. By ignoring competing
risks in the elderly population, the guidelines’ ‘‘one-size-
fits-all’’ approach promotes more health care, even when
it is potentially unnecessary.
Our findings should be interpreted with a few limi-
tations in mind. As with all observational studies,25
unmeasured factors can influence the outcome in this case
treatment intensity. To minimize confounding because of
patient differences, we used clinical registry data, which
allowed us to assess tumor stage and grade, arguably two
of the most important determinants of treatment inten-
sity.26 Further, we excluded patients undergoing radical
cystectomy within 6 months after diagnosis to minimize
misclassification associated with pathologic downstaging.
Patient preference for therapy, which can potentially con-
found our findings, cannot be captured in administrative
data. Thus, some may argue that overuse of health care
among lower risk patients may reflect patient demand and
expectations. However, patients are relatively uninformed
consumers27 compared with their physicians and they
generally rely on their doctor’s guidance. Thus, such pref-
erence could potentially be altered with better counseling
on the front-end. Because this study was set in the Medi-
care population, its applicability to patients younger than
65 years may be limited. However, bladder cancer occurs
mainly in theMedicare aged population,10 so our findings
are relevant to the population at greatest risk for develop-
ing the disease. Finally, our need to stratify the data based
on SEER expansion in 2000 resulted in a 7-year study of
SEER 13 data and a 3-year study of SEER 17 data. For ex-
amination of trends in expenditures and changes in demo-
graphics, the 3-year trends may be too short to reflect
significant changes that are, in fact, occurring.
CONCLUSIONS
Despite little change in underlying disease severity, expen-
ditures for early stage bladder cancer increased among
Medicare patients between 1993 and 2004. Physician
office visits and use of intravesical therapy were largely re-
sponsible for this increase. Although patient tumor stage
and grade are typically used to guide bladder cancer treat-
ment, we observed a mismatch between disease severity
and treatment intensity for many patients at the margins
of early stage bladder risk. Defining the optimal surveil-
lance and treatment strategies for early stage bladder can-
cer would be important for minimizing morbidity,
improving quality, and increasing efficiency.
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